Companies showcase innovative biotech at American Association for Cancer Research
pharmafile | April 17, 2023 | News story | Medical Communications |
Leading companies in the biotechnology sector will showcase their latest innovations at the American Association for Cancer Research (AACR) meeting being held in Florida, US, between 14-19 April. The three companies below are a selection of those with positive improvements in solid-tumour treatments.
Glycotope has announced it will present its glycol-engineered cell lines in a poster. This proprietary platform technology develops antibodies against proteins carrying tumour-specific carbohydrate structures.
Patrik Kehler, chief scientific officer of Glycotope, commented: “Our glyco-engineered cell lines provide the basis for a new generation of therapeutic antibodies with increased tumour specificity and safety for highly potent therapeutic approaches like ADCs, CARs and radiotherapeutics. Glycotope’s proprietary platform represents a versatile tool for target validation and screening of glycosylation-dependent protein binding antibodies.”
Innovent Biologics develops, manufactures and commercialises medicines for oncology, autoimmune, metabolic and ophthalmology diseases. At AACR, it will announce the final analysis results of phase 3 study ORIENT-15, which evaluated sintlimab in combination with chemotherapy for first-line treatment of eosophageal squamous cell carcinoma (ESCC). Data showed that sintilimab with chemotherapy “significantly improved” the median overall survival rate (mOS) with a 33.9% reduction in death.
Dr Hui Zhou, senior vice president of Innovent, stated: “The approval of immunotherapy has significantly improved the clinical benefits of standard treatments in patients with advanced ESCC… In this final analysis, the continued significant mOS benefits have been verified in advanced ESCC patients with an acceptable safety profile over time and further demonstrated that sintilimab as a first-line treatment option will benefit ESCC patients in China.”
Transgene designs and develops virus-based immunotherapies for oncology treatments and will highlight its promising preclinical data for its novel oncolytic virus TG6050 at AACR. The data demonstrates the ability of TG6050 to induce strong antitumour responses, leveraging the production of IL-12 and anti-CTLA4 antibody in the tumour.
Hedi Ben Brahim, Transgene’s CEO, said, “We have designed TG6050, a novel oncolytic virus encoding the IL-12 and an anti-CTLA4, to generate both innate and adaptive immune responses. These outstanding pre-clinical findings clearly support the clinical development of TG6050, which has recently started the phase 1 Delivir trial in patients with non-small cell lung cancer. We are confident that by generating similar effects in humans, TG6050 could become a new standard of care in patients with solid tumours.”
James Spargo
